MultiCell Technologies Inc.; | Stock Market News & Stocks to Watch from StraightStocks

MultiCell Technologies, Inc. (MCET.OB) is “One to Watch”

QualityStocks (August 20th, 2009) Writes:

Headquartered in Woonsocket, Rhode Island, MultiCell Technologies, Inc. is an integrated biopharmaceutical company. Trading on the OTCBB, their commitment is to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technologies. The company plans to pursue strategic alliances to better penetrate the various markets for their therapeutics.

The company’s drug development program focuses on the modulation of the immune system. Their lead drug candidates include drugs to treat multiple sclerosis (MS)-related chronic fatigue, relapsing-remitting MS, type-1 diabetes, and infectious disease. MultiCell Technologies, Inc.’s therapeutic pipeline includes MCT-125, which is directed at treating chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients.

The company also has their MCT-175, a targeting relapse-remitting MS. MCT-175 targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. It is in preclinical

...

Tags for this Post:
cell immortalization, cell immortalization technologies, cell-based assay systems, Diabetes, drug development, drug development technologies, Drug Discovery, fatigue, Infectious Disease, Influenza, integrated biopharmaceutical;, Market Commentary, Mississippi, MultiCell Technologies Inc.;, Multiple Sclerosis, producer, Rhode Island, Small & Micro Cap, targets disease, Woonsocket

Posted in Market Commentary, Small & Micro Cap | No Comments »

MultiCell Technologies, Inc. (MCET.OB) To Attack Liver Cancer

QualityStocks (March 19th, 2009) Writes:

MultiCell Technologies, Inc., an integrated biopharmaceutical company based in Rhode Island, announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc., a non-public Maryland-based medical research products company. The focus of the research will be the development of products for working with liver stem cells in the detection and treatment of liver cancer.

Although not one of the most common types of cancer in the U.S., liver cancer is still deadly. Nationwide there were over 21,000 new cases of primary liver cancer and intrahepatic bile duct cancer in 2008 according to the National Cancer Institute. Approximately 85% of those cases were fatal. Worldwide, liver cancer is more common due to the prevalence of hepatitis infection. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C, is the most common cancer in some parts of the world.

One of the problems in dealing with the disease

...